Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2016

View Archived Issues

Antares Pharma reports safety results from phase III trial of Quickshot testosterone

Vical starts phase II trial of VCL-HB01 in HSV-2 infection

FDA grants fast track designation to Axovant's intepirdine

Biogen completes rolling submission of NDA for nusinersen to FDA

Summit Therapeutics gains FDA fast track status for ezutromid

Versartis starts phase III trial of somavaratan in children with GHD

Abbvie submits sNDA to the FDA for ibrutinib

Cerecor acquires exclusive rights from Eli Lilly for CERC-611

FDA issues complete response letter for Remoxy extended-release capsules

HSP90 inhibitor/SN-38 drug conjugate STA-8666 effective in pediatric sarcoma models

Phase III COLUMBUS trial of encorafenib plus binimetinib meets primary endpoint

Novartis patents angiotensin AT2 receptor antagonists

Emory University discloses RNA-directed RNA polymerase inhibitors

Merck & Co. describes IRAK-4 inhibitors

BioMarin Pharmaceutical develops CGS inhibitors

LTT Bio-Pharma presents muscarinic M3 receptor antagonists

FDA grants emergency use authorization for Vela Diagnostics' Zika virus molecular assay

Alpha4betadelta GABARs exert anticonvulsant effects during puberty

Circulating C19MC microRNAs as biomarkers of infantile hemangioma

Idera Pharmaceuticals reports initial data from phase I/II trial of IMO-2125

Novel GLP-1/FGF21 dual agonist in preclinical studies

Pfizer not to split into two separate companies

Sciclone Pharmaceuticals reports advancements in several trials for thymalfasin and PT-112

New start-up Ilkos Therapeutics gets launched for the development of S-42909

Novel hybrid peptides as a promising strategy for type 2 diabetes

FDA places phase III Multikine trial on clinical hold

ARNT2 shows promise as a therapeutic target in MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...